Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours.
Nine dogs with primary bone tumours were treated with Samarium-153-EDTMP (Sm-153-EDTMP). Conventional treatment protocols were precluded by the size of the dogs and the owners' refusal of limb amputation. All the tumours were of the appendicular skeleton; 4 were confirmed osteosarcomas. The other 5 tumours were radiologically suspect for osteosarcoma. Bone scans were performed on all dogs using Technetium-99m-methylene diphosphonate (Tc-99m-MDP) before administration of Sm-153-EDTMP. Regions of interest were identified over the contralateral limb at the same site as the tumour and counts per pixel were recorded for the tumour and contralateral limb and expressed as a ratio. The dogs were given 1 injection of 37 MBq/kg (1 mCi/kg) of Sm-153-EDTMP intravenously. Thoracic and primary tumour site radiographs were taken at monthly or 2-monthly intervals to monitor progression of the primary tumour and search for evidence of metastasis. Two dogs showed no response to treatment, with an increase in bone pain, and were euthanased within 1 month. In 1 dog, a tumour of the scapula underwent complete involution and the dog is considered free of disease at 20 months post Sm-153-EDTMP treatment. The overall tumourcidal effect of a single dose of Sm-153-EDTMP on primary bone tumours was difficult to evaluate in this group of dogs, as, with one exception, all the primary tumours progressed over time and the dogs were euthanased. Pain control, for which Sm-155-EDTMP is used in man, was not evident, except in the dog that responded completely to treatment.
Milner
R J
RJ
Department of Medicine, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Dormehl
I
I
Louw
W K
WK
Croft
S
S
D000367:Age Factors; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000818:Animals; D001835:Body Weight; D001859:Bone Neoplasms / Q000175:diagnosis / Q000532:radiotherapy / Q000662:veterinary*; D004283:Dog Diseases / Q000175:diagnosis / Q000532:radiotherapy*; D004285:Dogs; D005260:Female; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000175:diagnosis / Q000532:radiotherapy / Q000662:veterinary*; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary; D013902:Radiography, Thoracic / Q000662:veterinary; D011868:Radioisotopes / Q000627:therapeutic use*; D012493:Samarium / Q000627:therapeutic use*; D012737:Sex Factors; D016896:Treatment Outcome
D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam